EBMT 2019 | The success story of bispecific and trispecific antibodies

Hermann Einsele

Beyond CAR T-cell therapy, bispecific and trispecific antibodies prove to be promising, which Hermann Einsele, MD, FRCP University Hospital Würzburg, Würzburg, Germany, discusses at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

Share this video  
Similar topics